MRN,MRNFacility,MedViewPatientID,PatientName,DOB,Sex,DrawnDate,DiagServiceID,AccessionNumber,HNAMOrderID,OrderTypeLocalID,OrderTypeMnemonic,TestTypeLocalID,TestTypeMnemonic,ResultDate,Value
"Unchanged1","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,CMV,1111111111111,XXX,2014-11-15 05:37:58.000,Test removal on basis of Order
"Unchanged2","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,M-DIFF,1111111111111,WBC Corr,2014-11-15 05:37:58.000,10000
"1000000004","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,Surgical Pathology Report,1111111111111,111111,2014-11-15 05:37:58.000,"PD-L1 test quoted Tumor proportion score: 10%"
"Unchanged3","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,Surgical Pathology Report,1111111111111,111111,2014-11-15 05:37:58.000,"PD-L1 test embedded characters Tumor proportion score: 10%"
"Unchanged4","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,Surgical Pathology Report,1111111111111,111111,2014-11-15 05:37:58.000,"PD-L1 <changed old record>"
"NewID_excluded_CBC_only","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,M-DIFF,1111111111111,WBC Corr,2014-11-15 05:37:58.000,10001
"NewID_excluded_CBC_only2","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,M-DIFF,1111111111111,WBC Corr,2014-11-15 05:37:58.000,10002
"NewID_excluded_CBC_only3","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,M-DIFF,1111111111111,WBC Corr,2014-11-15 05:37:58.000,10003
"NewRecord1","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,Surgical Pathology Report,1111111111111,111111,2014-11-15 05:37:58.000,PD-L1 new record
"NewRecord3","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,Surgical Pathology Report,1111111111111,111111,2014-11-15 05:37:58.000,"PD-L1 test embedded characters Tumor proportion score: 10%"
"NewRecord3","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,Solid Tumor NGS Report,1111111111111,111111,2014-11-15 05:37:58.000,"Center for Personalized DiagnosticsPerelman School of Medicine at the University of PennsylvaniaFusion Transcript Panel ReportDemographics:Case Number: XXXSpecimen Type: Paraffin Embedded TissueCollection Date: 1/1/1111 00:00Tissue Source: Lung, right lower lobeSpecimen Identifier: XX-XX-XXBlock: XX (XX)Estimated Tumor Percentage: 10-25%Specimen Quality Acceptable: YesRNA Quality Acceptable: NoIndication for Study: Lung adenocarcinomaINTERPRETATION AND COMMENTS:The RNA obtained from the submitted specimen is not adequate for testing. The extracted RNA is too degraded to meet the minimum input criteria for the assay. Alternate material is available, which may yield adequate RNA for sequencing. Please see separate report PD-19-665 when available.Please contact the attending faculty with any questions or concerns.COMMENT: This FINAL REPORT replaces the previously issued preliminary report.Clinical and pathologic correlation is recommended.XXXTitleVerified by: XXX MD               (Electronic Signature)Date/Time Verified: 11/11/1111 1:11 PMTEST DESCRIPTIONSolid Tumor Fusion Transcript Panel Targets:Gene                      Reference Sequence             Target ExonsAKT1                      NM_005163                           2,3,4,5ALK                        NM_004304                           2,4,6,10,16,17,18,19,20,21,22,23,26AXL                        NM_021913                           18,19BCOR                    NM_017745                            8BCOR                    NM_001123385                      6,7,8,12,14,15BRAF                     NM_004333                           1,2,3,7,8,9,10,11,12,13,15,16CALCA                   NM_001741                           3,4CAMTA1                NM_015215                           3, 8,9,10CCNB3                  NM_033031                            2,3,4,5,6CCND1                  NM_053056                            1,2,3,4,5CIC                        NM_015125                            18,19,20EGFR                    NM_005228                            1,7,8,9,16,19,20,24,25EML4                     NM_019063                            6,17EPC1                     NM_025209                            9,10,11ERBB2                   NM_004448                           4,5,23,24,25,26ERG                       NM_004449                           2,3,4,5,6,7,8,9,10,11ESR1                     NM_001122742                      3,4,5,6ESR1                     NM_000125                            6,8EWSR1                  NM_005243                           4,5,6,7,8,9,10,11,12,13,14FGFR1                   NM_015850                           2,3,4,5,6,7,8,9,10,11,12,17FGFR2                   NM_000141                           2,5,7,8,9,10,16,17FGFR3                   NM_000142                           3,5,8,9,10,16,17,18FOXO1                  NM_002015                            1,2,3FUS                       NM_004960                            3,4,5,6,7,8,9,10,11,13,14GLI1                       NM_005269                           4,5,6,7HMGA2                  NM_003483                           1,2,3,4,5JAZF1                    NM_175061                            2,3,4KRT20                   NM_019010                            2,5KRT7                     NM_005556                            2,7MEAF6                  NM_001270875                      4,5MET                       NM_000245                            2,4,5,6,13,14,15,16,17,21MKL2                     NM_014048                            11,12,13,14NCOA2                  NM_006540                            11,12,13,14,15,16NRG1                    NM_013957                            1,4,8NRG1                    NM_013962                            1NRG1                    NM_004495                            1,2,3,5,6NTRK1                   NM_002529                           2,4,6,8,10,11,12,13NTRK2                   NM_006180                           5,7,9,11,12,13,14,15,16,17NTRK3                   NM_001007156                     15NTRK3                   NM_002530                           4,7,10,12,13,14,15,16PDGFB                  NM_002608                            2,3PIK3CA                  NM_006218                           2PLAG1                   NM_002655                            1,2,3,4PMS2                     NM_000535                           5,7,9,10PPARG                  NM_015869                            1,2,3,5PTH                       NM_000315                            1, 3RAF1                     NM_002880                            4,5,6,7,8,9,10,11,12RET                       NM_020975                            8,9,10,11,12,13,14RET                       NM_020630                            2,4,6ROS1                     NM_002944                           2,4,7,31,32,33,34,35,36,37SLC5A5                 NM_000453                            4,8SS18                     NM_001007559                      4,5,6,8,9,10,11STAT6                   NM_001178078                      1,2,3,4,5,6,7,15,16,17,18,19,20TAF15                   NM_139215                            5,6,7TCF12                   NM_207036                            4,5,6TERT                     NM_198253                            2TFE3                     NM_006521                            2,3,4,5,6,7,8TFG                       NM_006070                            3,4,5,6,7THADA                  NM_022065                            24,25,26,27,28,29,30,36,37TMPRSS2             NM_005656                            1,2,3,4,5,6TMPRSS2             NM_001135099                      1,2USP6                     NM_004505                            1,2,3YWHAE                 NM_006761                            5XXXMETHODOLOGYXXXASSAY LIMITATIONSThis assay detects the presence or absence of oncogenic transcripts specifically targeted by the assay (see the table of targets for details). DISCLAIMERSPursuant to the requirements of CLIA 1988, this laboratory has established and verified the test’s accuracy and precision.REFERENCES:1. Anna Karlsson, Hans Brunnström, Kajsa Ericson Lindquist, Karin Jirström, Mats Jönsson, Frida Rosengren, Christel Reuterswärd, Helena Cirenajwis, Åke Borg, Per Jönsson,Maria Planck, Göran Jönsson, and Johan Staaf. Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget. 2015 Sep 8; 6(26): 22028–22037.2. Sarah K Tasian, Christian Hurtz, Gerald B Wertheim, Nathanael G Bailey, Megan S Lim, Richard C Harvey, I-Ming Chen, Cheryl L Willman, Rachel Astles, Alexis Zebrowski, Shalini C Reshmi, Marilyn M Li, Noelle V Frey, Selina M Luger, Martin Carroll, Alexander E Perl. High Incidence of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-like ALL) in Older Adults with B-ALL. Leukemia. 2017 Apr; 31(4): 981–984.3. Holodniy, M., S. Kim, D. Katzenstein, M. Konrad, E. Groves, and T.C. Merigan. 1991. Inhibition of human immunodeficiency virus gene amplification by heparin. J. Clin. Microbiol. 29:676-679.4. C. Schrader, A. Schielke, L. Ellerbroek and R. Johne. 2012. PCR inhibitors – occurrence, properties and removal. J. App Microbiol. 113(5):1015-1026.5. Berg, KD. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies. Dan Med J, 2016, 63, 12, B5319.6. Scheble VJ1, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol, 2010, 23, 8, 1061.7. Motonobu Saito, Kouya Shiraishi, Hideo Kunitoh, Seiichi Takenoshita, Jun Yokota, and Takashi Kohno. Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 2016 Jun; 107(6): 713–720.8. Kwak EL1, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28;363(18):1693-703.9. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017 Jan;19(1):4-23."
NewRecord4,"UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,Surgical Pathology Report,1111111111111,XXX,2014-11-15 05:37:58.000,"Last, First M                                111111111 XXX\r\n\r\n\r\nSurgical Pathology Report\r\n\r\n\r\nACCESSION:                COLLECTION DATE/TIME:    RECEIVED DATE/TIME:       PATHOLOGIST:\r\nXXXXXX             1/11/1111 11:11 EDT      1/11/1111 11:11 EDT       Last, First MD\r\n\r\n\r\nSurgical Pathology Final Report\r\n.Final Diagnosis:\r\nCase/s selected for testing on review: XX-20-XXXX, collected on        11/11/1111\r\n\r\nTissue appears adequate for PD-L1 (XXX) immunohistochemistry and CPD Solid Tumor NGS Panel.\r\n\r\nCPD test results will be separately reported.\r\nPD-L1 (XXX) immunohistochemical stain results will be reported in an addendum, see XX_XX-XXXX.\r\n\r\nThe case material was reviewed and the report verified by: Name\r\n\r\n(Electronic signature)\r\nReport Date/Time: 11/11/1111\r\n11:11 PM EDT\r\nCH\r\n\r\nXXX Lab\r\nAddress\r\nPhiladelphia PA 1111\r\n\r\nHistopathology and Cytopathology  processing performed at the Department of\r\nPathology and Laboratory Medicine, XXX,\r\nAddress, Philadelphia PA 11111.\r\n\r\n\r\n.Pathologist:\r\nName, MD\r\nName, MD\r\n\r\n.Gross Description:\r\nSpecimen requested for review: XX-XX-XXXX\r\n\r\nCases reviewed: XX-XX-XXXX\r\n\r\nDictated by: CERNER CERNER\r\nCH\r\n\r\n.Clinical Information:\r\nClinical Diagnosis: Metastatic breast cancer\r\nSpecimen Source:  Left supraclavicular lymph nodes\r\nRequested Tests: CPD Solid Tumor NGS Panel (Reflex), PD-L1 (XXXX) IHC\r\nPrevious molecular tests performed: N/A"
"NewRecord5Quoted","UID",1111111111,"ZZZ, ZZZ",1950006-16 00:00:00.000,M,2020-11-15 05:28:00.000,GL,00000111111111,1111111111,1111111111,Surgical Pathology Report,1111111111111,111111,2014-11-15 05:37:58.000,"Surgical Pathology Final Report\r\n.Final Diagnosis:\r\nSlides (9) labeled XXX from XXX (obtained on: 11/11/1111)\r\n1. Liver, biopsy:\r\nÂ· Adenocarcinoma, moderately differentiated, pancreatobiliary type, involving hepatic\r\nparenchyma.\r\nÂ· See note.\r\n\r\nThe case material was reviewed and the report verified by: Name, MD\r\n\r\n(Electronic signature)\r\nReport Date/Time: 11/11/1111\r\n111:11 PM EDT\r\nRIC\r\n\r\nNote:\r\nThe patient's history of a gallbladder carcinoma and hepatic masses on abdominal imaging is\r\nnoted.\r\n\r\nImmunohistochemical stains are performed the outside hospital and reviewed here.  The tumor\r\ncells stain positive for CK7 and negative for CK20, CDX2, and TTF1.  This immunoprofile and\r\nhistomorphology could be compatible with a pancreatobiliary primary, however, pathologic and\r\nradiographic correlation is needed.\r\n\r\nImmunohistochemical stains for DNA mismatch repair proteins MLH1, PMS2, MSH2 and MSH6 were\r\nperformed at the outside hospital and reviewed here.  Results are as follows:\r\n\r\nMLH1: Nuclear staining is present in tumor\r\nPMS2: Nuclear staining is present in tumor\r\nMSH2: Nuclear staining is present in tumor\r\nMSH6: Nuclear staining is present in tumor\r\n\r\nInterpretation:  These findings imply a low probability of a microsatellite instability-high\r\n(MSI-H) tumor.\r\n\r\n"
